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Abstract 
Background: Although the implantable cardiac defibrillator (ICD) remains the main 
therapy in Brugada syndrome (BrS), it does not reduc  life-threatening ventricular 
arrhythmia. Based on pathophysiological mechanisms, hydroquinidine (HQ) has been 
suggested for the effective prevention of arrhythmia. 
Objective: To provide evidence-based data supporting HQ use to prevent life threatening 
ventricular arrhythmia in high-risk patients with BrS. 
Methods: We performed a prospective multicentre randomised (HQ vs. placebo) double-
blind study with two 18-month cross-over phases in patients with BrS and implanted with an 
ICD.  
Results: Among the 50 patients enrolled [mean age 47.0±11.4 years; 42 (84%) male], 26 
(52%) fully completed both phases. Thirty-four (68%) presented HQ-related side effects, 
mainly gastrointestinal, which led to discontinuation of the therapy in 13 (26%). HQ has 
lengthened the QTc interval (409±32 vs. 433±37ms; P=0.027) and increased the 
repolarization dispersion as evaluated by the Tpe max in precordial leads (89±15 vs. 
108±27ms; P<0.0001) with no significant changes in J-point elevation. During the 36-
month follow-up, 1 appropriate ICD shock (0.97% event per year), 1 self-terminating 
ventricular fibrillation and 1 inappropriate ICD shock occurred under placebo therapy. No 
arrhythmic events were reported under HQ therapy. 
Conclusion: Although HQ appears to be effective in preventing l fe-threatening ventricular 
arrhythmia, it could not be an alternative for ICD implant. Its frequent side effects greatly 
reduce its probable compliance and therefore do not reveal a significant effect. HQ increases 
repolarization dispersal with no changes in BrS pattern, which could indicate a more 
complex action of HQ than its Ito blocking effect alone. 
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Introduction 
Since the first description of Brugada syndrome1 (BrS), our understanding of 
the pathophysiological mechanisms of this inherited arrhythmia disease has constantly 
progressed.2–5 Although risk stratification of sudden cardiac death (SCD) has been 
improved in line with this understanding,6–8 management of patients affected with 
BrS remains mainly dependent on an implantable cardioverter defibrillator (ICD) with 
a high rate of complications.9 βblockers were evaluated to be an alternative for ICD
implant but have failed to prove their efficiency.10 
Hydroquinidine (HQ), a class IA antiarrhythmic, has been used for decades in 
the management of arrhythmia.11 Its safety and efficacy in patients with idiopathic 
ventricular fibrillation (VF)12, early repolarization syndrome2 or BrS have been 
reported by different retrospective studies but remain a matter of debate since it has 
never been investigated by randomised and multicenter studies.13–18 
Our aim was to provide evidence-based data to support HQ use to prevent life 
threatening ventricular arrhythmia in high-risk patien s with BrS in multicenter 
prospective randomised double-blind study. 
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Methods 
Population 
Patients were recruited from February 2009 to November 2011, from 13 
tertiary French university hospitals. Protocol approval was obtained from institutional 
ethical committees. Written informed consent was obtained from all patients before 
their inclusion. This clinical trial was registered at https://clinicaltrials.gov/ 
(NCT00927732). 
All our BrS study patients were considered at high-risk and all had an ICD 
implanted due to the following: previous aborted SCD or documented ventricular 
tachyarrhythmias (group A); previous unexplained syncope supposed to be of an 
arrhythmic origin (group B); spontaneous type 1 BrS ECG pattern with a positive 
electrophysiological study (EPS) (group C). Patients i  group A or B could display 
both spontaneous or drug-induced type 1 BrS ECG pattern. EPS were conducted with 
a maximum of three ventricular extrastimuli with a minimum coupling interval of 
200ms from at least one right ventricular site. EPS was considered positive if VF 
and/or sustained ventricular tachycardia (VT) was induced. 
Patients already on daily HQ medication above 900mg or below 300mg were 
excluded as those with manifestations of HQ hypersensitivity [appearance of 
hypotension, fever, prolongation of QTc interval >40ms (arbitrarily chosen) or 
prolongation of QRS duration >25%].11,19,20 HQ hypersensitivity test (clinical and 
ECG monitoring for 3 hours after a single intake of HQ 300mg) was performed in 
every included patient not on chronic HQ therapy before.  
After a 7-day washout period, patients were randomised to placebo or HQ. A 
crossover was performed after 18 months, separated by a second 7-day washout 
period. Optimal HQ dosages were assessed in each patient to achieve HQ blood level 
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range from 3 to 6 µmol/L, commonly consider as therapeutic and reported in previous 
studies.13,16,17 
A core lab of 3 expert physicians blinded to patient clinical and 
pharmacological status reviewed ECG at baseline and during follow-up. Quantitative 
measurements of electrocardiographic parameters were assessed at baseline, after an 
acute intake and on chronic HQ therapy (supplementary methods for ECG 
measurement’s details). 
Follow-up consultations, including ECG and ICD interrogation, were planned 
in each phase of the crossover study at 1, 6, 12 and 18 months. In case of an 
appropriate ICD shock, the patient was switched to phase 2 after a 7-day washout 
period or ended the study if he/she had already been in phase 2. 
Endpoints 
The primary endpoint was the time to the first appro riate ICD shock. 
Secondary endpoints were evaluation of inappropriate shocks, self-terminating 
VT/VF episodes, death from all causes, occurrence of supra-ventricular tachycardia 
(SVT), syncope without arrhythmic events after ICD interrogation and adverse events 
under HQ therapy. 
Statistical Analysis 
Data were analysed with SAS packages (SAS Institute Inc., Cary, NC). Chi2 
or Fisher's exact tests were used to compare categorical variables. The t-test, Mann-
Whitney, Kruskall-Wallis tests were performed to test for differences in continuous 
parameters. Means with standard deviations or medians with quartile data are 
presented as appropriate. A two-sided P-value<0.05 was considered as statistically 
significant in all tests. 
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Results 
Study population  
Among the 78 patients screened, 50 were randomised [m an age: 47.0±11.4 
years, 42 (84%) male] as shown in Figure 1. The clinical characteristics and baseline 
ECG parameters for all of the 50 randomized patients and according to their 
subgroups are summarized in Table 1. 
Twenty-six (52%) patients were randomised to phase 1 HQ and 24 (48%) to 
phase 1 placebo. Among the 13 (26%) patients who stopped therapy during phase 1, 8 
(62%) were on HQ. Nine (69%) stopped because of adverse events, which were 
essentially gastrointestinal (n=6). Eleven (22%) patients stopped therapy during phase 
2 including 8 (73%) on HQ. The main reason was adverse vents (n= 10; 91%), which 
were essentially gastrointestinal (n=5). 
Finally, 26 (52%) patients fully completed both phases (36 months) without 
discontinuation of medication. 
Occurrence of arrhythmias 
Mean follow-up was respectively 376±248 days and 377±235 days under HQ 
and placebo therapy. 
No patient on HQ presented an appropriate ICD shock. One patient (group A) 
on placebo experienced an appropriate ICD shock (event rate 0.97% per year) without 
recurrence during the following 18 months while on HQ (900mg daily; HQ blood 
level: 3µmol/L), but he experienced a second appropriate ICD shock 3 days after 
having stopped his HQ during the washout period (after the end of phase 2). This 
patient was diagnosed at age 28 after an aborted SCD and presented with a 
spontaneous BrS type 1 ECG pattern. His specific ECG parameters under placebo 
then HQ therapy are shown in supplementary material Table 1. 
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One self-terminating VF episode occurred in a patient (group B) while on 
placebo and one inappropriate ICD shock for SVT in a patient (group C) while on 
placebo. Fourteen patients (28%) presented SVT during follow-up, of whom 8 (57%) 
were on HQ therapy and 6 (43%) on placebo (P=0.33). Two (4%) patients died during 
the study, one (group B) from a traumatic brain injury and the other (group A) 
secondary to a neuromuscular disease. 
HQ therapy 
The mean HQ daily dosage was 738±174mg with a mean HQ blood level of 
3.14±0.63µmol/L. Twenty-nine (58%) patients were under HQ 600mg daily, 19 
(38%) under 900mg and 2 (4%) under 1200mg with mean HQ blood levels 
respectively of 3.44±0.65µmol/L, 2.84±0.46µmol/L and 3.20±0.71µmol/L. 
Thirty-four (68%) patients reported adverse events during their treatment with 
HQ. Thirteen (26%) had to stop the medication for HQ-related side effects, which 
were mainly gastrointestinal (n=10; 77%) but also photophobia (n=2; 15%) and 
photosensitivity (n=1; 8%). Three stopped HQ for adverse events not related to HQ 
therapy. Side effects were significantly more frequnt with HQ therapy (Table 2). 
Patients who experienced side effects were on a higher mean daily dosage of 
HQ (768±186mg vs. 675±136mg; P=0.04) but no differences were found regarding 
age, sex, clinical presentation, ECG parameters or HQ blood levels (3.09±0.46µmol/L 
vs. 3.28±0.82µmol/L; P=0.25). 
Acute HQ-induced ECG changes 
Among the 50 randomised patients, 48 (96%) underwent a hypersensitivity 
HQ test whereas 2 (4%) were already on HQ therapy. QT (387±27 vs. 414±35ms; 
P<0.0001), QTc intervals (404±29 vs. 417±29ms; P=0.027) and Tpe max (95±18 vs. 
107±22ms; P<0.001) were significantly longer 3 hours after an acute intake of HQ 
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300 mg. No significant changes were observed on J-point elevation. Details are 
provided in Table 3 and according to subgroup in supplementary material Table 2. 
Chronic HQ-induced ECG changes 
Among the 50 randomised patients who underwent boththerapies (HQ and 
placebo), QT (388±29 vs. 411±35ms; P<0.0001), QTc intervals (409±32 vs. 
433±37ms; P=0.027), Tpe max (89±15 vs. 108±27ms; P<0.0001) and Tpe dispersion 
were significantly longer while on chronic HQ therapy. No significant changes were 
observed in J-point elevation in any of the right precordial leads. Except for QTc 
interval [417±29ms (acute) vs. 433±37ms (chronic); P<0.0001], no ECG parameters 
appeared to be different under acute and chronic HQ therapy. Details are provided in 
Table 3 and according to subgroup in supplementary material Table 3. Except for 
QTc (421±35ms vs. 443±36ms; P<0.001), no significant relevant differences were 
observed comparing patients under 600mg daily of HQ with others (>600mg daily). 
Details are presented in supplementary material Tab e 4. An example of ECG HQ-
induced changes is shown in Figure 2. 
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Discussion 
Since there was no occurrence of any ventricular arrhythmia in patients under 
HQ, HQ appears to be quite effective in BrS. However, statistical significance 
compared to placebo was not observed, principally owing to a lower arrhythmic event 
frequency than expected (only one patient on placebo presenting with ventricular 
arrhythmia) and to HQ-related adverse events, which were frequent and causing 
interruption of therapy in a significant number of cases. 
HQ-related side effects 
HQ-related side effects, especially gastrointestinal, have been broadly 
described in the literature but tend to be fewer than those we observed. Belhassen14 
reported a 36% adverse events rate in patients on a mean daily dosage of quinidine 
bisulfate of 1483±240mg. Among patients on lower HQdosages (618±72 mg/day), 
Bouzeman16 noted a low 6% rate of major HQ intolerance which led to a 
discontinuance of therapy. Mizusawa21 observed no major intolerance in the 14 
patients on HQ daily dosage between 300 to 600mg (mean HQ blood level: 
1.55µg/mL) with reported success of 44% in preventing VF inducibility. 
In our study, with a mean HQ daily dosage of 738±174 mg, we observed a 
larger proportion of 58% HQ-related adverse events that led to a discontinuance of 
therapy in 26%. Nonetheless, we were still on the lower border of our therapeutic HQ 
blood level range (3.14±0.63µmol/L). One could argue that the lower the dosage 
used, the lower the side effects rate, but lower HQ efficacy may also be expected. 
This lower HQ dosage have been suggested to be efficient in case series, but without 
further evidences, the difficult question of defining optimal HQ daily dosages remain 
to be assessed22. 
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Apart from higher HQ dosage, we found no differences b tween patients who 
suffered from adverse events and others. Thus, our data did not support a genotype or 
phenotype relation with side-effects. 
 
HQ-induced ECG changes 
Aside from its INa and IKr blocking effect, HQ presents with an Ito blocking 
effect that has been suggested to support it potential therapeutic role in patients with 
BrS13,23. Indeed, according to Antzelevitch et al.,23 the transmural heterogeneity of Ito 
current, which induces repolarization heterogeneity, plays a key role in the occurrence 
of type 1 BrS ECG pattern as well as in the arrythmogenicity by facilitating phase 2 
re-entry2,24. Tpe has been used as an ECG marker of this transmural repolarization 
dispersion25 and appears to be a useful tool to evaluate repolarization processes and 
the effects of HQ in BrS patients. A prolonged Tpe int rval should be correlated with 
increased transmural repolarization heterogeneity that may enhance the substrate for 
phase 2 re-entry. Confirming this hypothesis, according to Maury,26 this prolonged 
Tpe and Tpe max denote a higher risk of arrhythmic events in BrS patients. 
The present study showed that HQ-induced ECG changes appear promptly 
after an acute intake and are maintained under chronic therapy. This correlates the 
clinical efficacy of HQ observed during electrical storms in BrS patients27. We 
expected a reduction of repolarization heterogeneity in BrS patients who underwent 
HQ therapy. However, although HQ lengthened QT and QTc interval, it also 
increased the repolarization dispersion as evaluated by the Tpe and Tpe max. 
Additionally, in opposition to previous clinical reports,28 we did not find any 
significant effect on J-point elevation. 
This effect was considered as unexpected based on the idea that BrS 
pathophysiology involved only a repolarization disorder.23 However, as we now 
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know, repolarization and depolarisation disorders are both involved.29 Therefore, 
these ECG modifications could denote a more complex role than simply a selective 
and exclusive Ito blocking effect of HQ in BrS patients. Indeed, IKr blocking effect has 
been demonstrated to prolong Tpe interval with a similar but smaller effect on ST 
segment interval19. Interestingly, the multi-ion channel block of quinidine is 
concentration-dependent and begins with a IKr blocking effect before appearance of 
significant block in other sodium, calcium and potassium channel including Ito
30. This 
could explain the increase in Tpe interval without modification of J wave amplitude 
that we observed in our study. Among previous studies about BrS, both low and high 
dosages of HQ have been used, generating various effects on patient’s ECGs. In our 
study, HQ-induced ECG changes were similar (except for QTc) regardless of daily 
HQ dosage.  
 Altogether, this suggests that the global ionic effect of HQ may explain the 
variability in ECG modifications among studies.13,23 As a consequence, assuming HQ 
is efficient to prevent arrhythmia in BrS, its effect does not seem to be only and 
directly due to Ito inhibition. 
Study Limitations 
When the QUIDAM study was designed, only few databases that included a 
large number of patients were available and EPS to test for VF inducibility was 
commonly used as a tool for risk stratification6,31. Thence, we expected an arrhythmic 
event rate to be as high as 1% monthly in our selected population. This was weighted 
by our proper evaluation data of arrhythmic risk in patients with BrS which was 
subsequently published in the FINGER study,6 but that was still overestimated in 
comparison to current knowledge. 
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According to Hermida13 et al., one could initially consider a risk reduction of 
arrhythmic events up to 70% with HQ with 10% adverse events leading to 
discontinuation of therapy. On this basis, with an α=5% and β=20%, and based on 
expected arrhythmic rate at study onset, 200 patients were thought necessary to reach 
statistical significance within a 24-month follow-up. This was extended to 36 months 
to reach statistical significance due to the lower than expected arrhythmic event rate. 
However, when both were combined, the real arrhythmic event rate and HQ-related 
side effects leading to discontinuation of therapy, the estimated sample size to reach 
statistical difference was evaluated as high as 1,800 patients. This extremely high and 
not reasonably achievable number led to the premature termination of the QUIDAM 
study. 
The future of HQ 
Despite previous encouraging clinical and experimental studies,13,14,23 the 
QUIDAM study was not able to provide evidence-based data to support its efficacy 
and safety in high-risk BrS patients. The use of HQ has been suggested in lower-risk 
Brs patients.16,17 However, considering the low arrhythmic event rate nd a similar 
HQ-related side-effect rate, demonstration of a significant effect appears unachievable 
in such population. 
Still, as shown by our patient who experienced one (two if wash-out period is 
included) appropriate ICD shock(s) on placebo, our st dy supports the HQ individual 
efficacy. Retrospective studies have reported the well-tolerance and the likely 
efficiency of long-term HQ therapy17,32. Anguera33 et al. noted that quinidine could be 
useful to reduce, but not supress, the burden of ventricular arrhythmias with still few 
patients who experienced ICD shocks. 
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Considering the progress of defibrillation devices l ading to less ICD-related 
complications (especially with the sub-cutaneous ICD), the development of catheter 
ablation in BrS patients and the virtual impossibility to demonstrate the efficacy of 
HQ therapy, it is likely that its use will remain restricted to secondary prevention in 
patients already implanted with an ICD or who refuss or has no access to one.  
According to current evidence based data, HQ could not be considered as an 
alternative for ICD implant in patients with high-risk BrS, even considering the high 
rate of ICD-related complications in such population. Define precise daily HQ dose 
and characteristics of patients whom benefit from HQ therapy would be of a great 
help. 
We advise to consider, if available, the use of an individual well tolerated HQ 
dosage in BrS patients with ICD and recurrent ventricular arrhythmias. If such a 
therapy should fail or be badly tolerated, catheter ablation might be an adjuvant. 
However, several studies are ongoing and will provide data in the future to better 
place catheter ablation among the therapeutic arsenl for BrS patients.34  
Finally, in the paediatric BrS population where an ICD implant could be 
challenging and HQ appears to be well tolerated, this therapy could be a temporary 
alternative.35 
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Conclusion 
The QUIDAM study was the first prospective randomized double-blind study 
aiming to provide strong data to support HQ use in the management of high-risk BrS 
patients. The conductive idea was to be capable of offering a safe alternative to ICD 
implants. Unfortunately, frequent HQ-related side eff cts and rare arrhythmic events 
have made it difficult to conduct large studies to pr ve HQ efficacy. This has led to a 
premature termination of the QUIDAM study without demonstrating the efficacy of 
this drug. According to current data, HQ could not be considered as an alternative to 
ICD implantation in high-risk patients with BrS. 
However, we did observe ECG changes under therapy such as lengthening of 
the Tpe interval with no effect on J-point elevation, which suggest a more complex 
role than a selective and exclusive Ito blocker effect of HQ in BrS patients. This 
supports the idea that BrS pathophysiology involves more complex mechanisms than 
only a repolarization disorder. 
Regardless of these shadow areas, these considerations should not stop its use 
in daily clinical practice, especially for the management of BrS patients with recurrent 
ventricular arrhythmia or electrical storms. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17
Acknowledgements 
We thank all the patients who agreed to be involved on this study as the “Centre de 
reference des maladies rythmiques héréditaires” for thei  help. 
This study was performed with grant from Health French Ministry (clinical research 
hospital program BRD/06/02-D-1; 2005). 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
References 
1.  Brugada P, Brugada J: Right bundle branch block, persistent ST segment 
elevation and sudden cardiac death: a distinct clinical and electrocardiographic 
syndrome. A multicenter report. J Am Coll Cardiol 1992; 20:1391–1396.  
2.  Antzelevitch C: J wave syndromes: Molecular andcellular mechanisms. J 
Electrocardiol 2013; 46:510–518.  
3.  Le Scouarnec S, Karakachoff M, Gourraud J-B, et al.: Testing the burden of 
rare variation in arrhythmia-susceptibility genes provides new insights into molecular 
diagnosis for Brugada syndrome. Hum Mol Genet 2015; 24:2757–2763.  
4.  Bezzina CR, Barc J, Mizusawa Y, et al.: Common variants at SCN5A-
SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high 
risk of sudden cardiac death. Nat Genet 2013; 45:104–1049.  
5.  Gourraud J-B, Barc J, Thollet A, Le Scouarnec S, Le Marec H, Schott J-J, 
Redon R, Probst V: The Brugada syndrome: A rare arrhythmia disorder with complex 
inheritance. Front Cardiovasc Med 2016; 3:9.  
6.  Probst V, Veltmann C, Eckardt L, et al.: Long-term prognosis of patients 
diagnosed with Brugada syndrome: Results from the FINGER Brugada syndrome 
registry. Circulation 2010; 121:635–643.  
7.  Adler A, Rosso R, Chorin E, Havakuk O, Antzelevitch C, Viskin S: Risk 
stratification in Brugada syndrome: Clinical characteristics, electrocardiographic 
parameters, and auxiliary testing. Heart Rhythm 2016; 13:299–310.  
8.  Probst V, Chatel S, Gourraud J-B, Marec HL: Risk stratification and 
therapeutic approach in Brugada syndrome. Arrhythmia Electrophysiol Rev 2012; 
1:17–21.  
9.  Sacher F, Probst V, Maury P, et al.: Outcome aft r implantation of a 
cardioverter-defibrillator in patients with Brugada syndrome: A multicenter study-
Part 2. Circulation 2013; 128:1739–1747.  
10.  Nademanee K: Defibrillator versus beta-blockers fo  unexplained death in 
Thailand (DEBUT): A randomized clinical trial. Circulation 2003; 107:2221–2226.  
11.  Wood AJ, Grace AA, Camm AJ: Quinidine. N Engl J Med 1998; 338:35–45.  
12.  Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M: Effects of 
electrophysiologic-guided therapy with Class IA anti rrhythmic drugs on the long-
term outcome of patients with idiopathic ventricular fibrillation with or without the 
Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10:1301–1312.  
13.  Hermida J-S, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney 
P, Di Fusco S, Rey J-L, Cauchemez B, Leenhardt A: Hydroquinidine therapy in 
Brugada syndrome. J Am Coll Cardiol 2004; 43:1853–1860.  
14.  Belhassen B, Glick A, Viskin S: Efficacy of quinidine in high-risk patients 
with Brugada syndrome. Circulation 2004; 110:1731–1737.  
15.  Viskin S, Wilde AAM, Tan HL, Antzelevitch C, Shimizu W, Belhassen B: 
Empiric quinidine therapy for asymptomatic Brugada syndrome: Time for a 
prospective registry. Heart Rhythm 2009; 6:401–404.  
16.  Bouzeman A, Traulle S, Messali A, Extramiana F, Denjoy I, Narayanan K, 
Marijon E, Hermida J-S, Leenhardt A: Long-term follow-up of asymptomatic 
Brugada patients with inducible ventricular fibrillation under hydroquinidine. 
Europace 2014; 16:572–577.  
17.  Belhassen B, Rahkovich M, Michowitz Y, Glick A, Viskin S: Management of 
Brugada syndrome: thirty-three-year experience using electrophysiologically guided 
therapy with Class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol 2015; 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19
8:1393–1402.  
18.  Probst V, Gourraud J-B: Quinidine in Brugada syndrome: still a long way to 
go…. Circ Arrhythm Electrophysiol 2015; 8:1309–1310.  
19.  Johannesen L, Vicente J, Mason JW, et al.: Differentiating drug-induced 
multichannel block on the electrocardiogram: randomized study of dofetilide, 
quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 2014; 96:549–558.  
20.  Roden DM: Predicting drug-induced QT prolongation and torsades de pointes. 
J Physiol 2016; 594:2459–2468.  
21.  Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M: Effects of low-dose 
quinidine on ventricular tachyarrhythmias in patiens with Brugada syndrome: low-
dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 2006; 
47:359–364.  
22.  Márquez MF, Bonny A, Hernández-Castillo E, De Sisti A, Gómez-Flores J, 
Nava S, Hidden-Lucet F, Iturralde P, Cárdenas M, Tonet J: Long-term efficacy of low 
doses of quinidine on malignant arrhythmias in Brugada syndrome with an 
implantable cardioverter-defibrillator: a case series and literature review. Heart 
Rhythm 2012; 9:1995–2000.  
23.  Yan G-X, Antzelevitch C: Cellular basis for the Brugada syndrome and other 
mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 
1999; 100:1660–1666.  
24.  Gaborit N, Wichter T, Varro A, Szuts V, Lamirault G, Eckardt L, Paul M, 
Breithardt G, Schulze-Bahr E, Escande D, Nattel S, Demolombe S: Transcriptional 
profiling of ion channel genes in Brugada syndrome and other right ventricular 
arrhythmogenic diseases. Eur Heart J 2009; 30:487–496.  
25.  Antzelevitch C, Yan GX, Shimizu W: Transmural dispersion of repolarization 
and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J 
Electrocardiol 1999; 32 Suppl:158–165.  
26.  Maury P, Sacher F, Gourraud J-B, et al.: Increased Tpeak-Tend interval is 
highly and independently related to arrhythmic events i  Brugada syndrome. Heart 
Rhythm 2015; 12:2469–2476.  
27.  Probst V, Evain S, Gournay V, Marie A, Schott J-J, Boisseau P, Le Marec H: 
Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated 
by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol 2006; 
17:97–100.  
28.  Alings M, Dekker L, Sadée A, Wilde A: Quinidine induced 
electrocardiographic normalization in two patients with Brugada syndrome. Pacing 
Clin Electrophysiol 2001; 24:1420–1422.  
29.  Tokioka K, Kusano KF, Morita H, Miura D, Nishii N, Nagase S, Nakamura K, 
Kohno K, Ito H, Ohe T: Electrocardiographic parameters and fatal arrhythmic events 
in patients with Brugada syndrome. J Am Coll Cardiol 2014; 63:2131–2138.  
30.  Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, 
Strauss DG: Comprehensive T wave morphology assessment in a randomized clinical 
study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc 2015; 4.  
31.  Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P: 
Long-term follow-up of individuals with the electrocardiographic pattern of right 
bundle-branch block and ST-segment elevation in precordial leads V1 to V3. 
Circulation 2002; 105:73–78.  
32.  Adler A, Olde Nordkamp L, Crotti L, et al.: Empiric quinidine for 
asymptomatic Brugada syndrome—preliminary results of an international registry. 
Heart Rhythm 2012; 9:1918–1919.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20
33.  Anguera I, García-Alberola A, Dallaglio P, Toquero J, Pérez L, Martínez JG, 
Peinado R, Rubín JM, Brugada J, Cequier A: Shock reduction with long-term 
quinidine in patients with Brugada syndrome and malign nt ventricular arrhythmia 
episodes. J Am Coll Cardiol 2016; 67:1653–1654.  
34.  Nademanee K, Hocini M, Haïssaguerre M: Epicardial substrate ablation for 
Brugada syndrome. Heart Rhythm 2017; 14:457–461.  
35.  Andorin A, Behr ER, Denjoy I, et al.: Impact of clinical and genetic findings 
on the management of young patients with Brugada syndrome. Heart Rhythm 2016; 
13:1274–1282.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 21
Figure legends 
Figure 1: Flow-chart of the QUIDAM study. 
Figure 2: Twelve-lead ECG with no medication (baseline), after an acute intake of 
hydroquinidine (HQ) and under chronic HQ therapy. An increased QTc and Tpe max 
was observed while on both HQ therapies. ECG-speed 25mm/s and voltage 
10mm/mV. 
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Tables 
Table 1: Clinical characteristics and ECG parameters on inclusion. Group A: past 
history of SCD; Group B: past history of syncope; Group C: asymptomatic with 
spontaneous type 1 ECG pattern and positive electrophysiological study. 
  
Group A Group B Group C Total 
n=6 (12%) n=26 (52%) n=18 (36%) n=50 (100%) 
Clinical characteristics   
Age on diagnosis, years 43.7±12.6 45.5±11.9 50.6±9.8 47.0±11.4 
Male, n (%) 5(83) 22(85) 15(83) 42(84) 
Family history of SCD, n (%) 0 6(23) 9(50) 15(30) 
Spontaneous Type 1 ECG pattern, n (%) 5(83) 13(50) 18(100) 36(72) 
Dual Chamber ICD, n (%) 0  2(8) 1(5) 3(6) 
VF zone >200 bpm, n (%) 6(100) 23(88) 18(100) 47(94) 
Presence of a VT zone, n (%) 3(50) 3(12) 5(28) 11(22) 
SCN5A mutation, (n=43), n (%) 0/5(0) 4/22(18) 5/16(31) 9/43(21) 
ECG parameters on inclusion    
Heart Rate (bpm) 72±11 72±10 67±10 70±11 
PR (ms) 180±13 190±32 180±36 185±32 
QRS (ms) 108±11 112±22 102±36 108±21 
QT (ms) 393±48 382±32 383±31 383±33 
QTc Bazett (ms) 424±42 425±37 397±37 415±39 
Maximum J-point elevation (mm) 4.0±2.3 3.5±1.4 3.2±1.2 3.5±1.5 
SCD: sudden cardiac death; ECG: electrocardiogram; ICD: implantable cardioverter defibrillator: VF: ventricular fibrillation; 
VT: ventricular tachycardia  
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Table 2: Adverse events in the randomised population (n=50) of the QUIDAM study 
according to placebo or hydroquinidine therapy. 
  Placebo HQ P-value 
Duration of therapy, days 377±235 376±248 0.23 
AE leading to stop therapy, n (%) 3(6) 16(32) 0.002 
Gastrointestinal, n (%) 1(2) 10(20) 0.008 
Other existing AE under HQ, n (%) 0 3(6) 0.24 
photophobia 0 2(4) - 
photosensitivity 0 1(2)  - 
AE unrelated to HQ, n (%) 2(4) 3(6) 1 
AE not leading to stop therapy, n (%) 5(10) 18(36) 0.004 
Gastrointestinal, n (%) 2(4) 16(32)  0.0004 
Other existing AE on HQ, n (%) 3(6) 9(18) 0.12 
photophobia 0 2(4) - 
photosensitivity 0 2(4) - 
tinnitus 0 2(4) - 
headache 0 1(2) - 
vertigo 1(2) 1(2) - 
fatigue 2(4) 1(2) - 
AE unrelated to HQ, n (%) 0 7(14) 0.01 
AE: adverse events; HQ: hydroquinidine
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Table 3: Standard and repolarization dispersion ECG parameters measured before 
(Before HQ), 3 hours after (Acute HQ) a 300mg intake of hydroquinidine, under 
placebo and chronic hydroquinidine therapy. 
  
Before HQ 
(n=48) 
Acute HQ 
(n=48) 
Placebo 
(n=50) 
Chronic HQ 
(n=50) 
P-value 
Standard ECG parameters           
Heart Rate (bpm) 67±10* 62±10*† 68±10 69±10† *0.032; †0.0004 
PR (ms) 182±31 185±31 182±36 186±31 - 
QRS (ms) 103±17 104±18 103±17 103±16 - 
QT (ms) 387±27* 414±35* 388±29† 411±35† *†<0.0001 
QTc Bazett (ms) 404±29* 417±29*† 409±32‡ 433±37†‡ *0.027; †‡<0.0001 
Maximum J-point elevation (mm) 1.6±1.5 1.7±1.6 1.8±1.4 1.8±1.5 - 
Tpe (ms)           
V1 79.3±19.9 84.1±24.5 69.7±16.0* 77.4±20.9* *0.0055 
V2 85.2±19.4* 91.1±25.0* 74.5±16.8† 87.2±21.5† *0.046; †<0.0001 
V3 82.5±15.2* 92.0±18.8* 80.0±17.1† 95.7±29.5† *0.002; †<0.0001 
V4 79.4±15.7* 88.6±20.5* 78.6±13.8† 87.8±25.1† *0.002; †0.0013 
V5 76.6±16.6* 87.2±23.6* 75.4±15.2† 83.8±23.9† *<0.001; †0.0028 
V6 73.4±17.0* 83.4±20.4* 69.5±12.7† 79.0±19.1† *0.01; †<0.0001 
Tpe/QTc         - 
V1 0.205±0.046 0.205±0.046* 0.176±0.040 0.181±0.043* 0.01 
V2 0.218±0.032 0.218±0.032 0.192±0.040 0.208±0.048 - 
V3 0.222±0.037 0.222±0.037 0.206±0.046 0.225±0.064 - 
V4 0.214±0.036 0.214±0.036 0.201±0.033 0.207±0.053 - 
V5 0.205±0.039 0.214±0.047* 0.193±0.034 0.196±0.048* *0.04 
V6 0.197±0.040 0.209±0.048* 0.180±0.030 0.187±0.038* *0.004 
Tpe dispersion (ms) 31.0±15.8 36.0±19.0 29.6±13.1* 42.3±23.6* *<0.0001 
Tpe max (ms) 94.8±18.3* 106.6±22.4* 89.4±15.2† 107.7±26.6† *<0.001; †<0.0001 
No comparisons were made between acute HQ and Placebo 
ECG: electrocardiogram; HQ: hydroquinidine  
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Figure 1 
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